Generics producer Par Pharmaceuticals (NYSE: PRX) has been snapped up by a global private equity firm TPG in a deal that values the company at $1.9 billion, the tenth largest deal for the year to date, according to data from Dealogic. Par may well try to get a better deal since it’s got until August […]
Par Pharmaceuticals (NYSE: PRX) completed its third generics deal in six months with the $20.5 million acquisition of a drug developer and manufacturer based in India. Edict Pharmaceuticals has 11 abbreviated new drug applications filed with the U.S. Food and Drug Administration. In November, Par Pharmaceuticals completed its $410 million deal to acquire Anchen Pharmaceuticals, […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.